News & Updates

SET-Office: Unique Concept with exclusive control on processes.
Abiogenesis Clinpharm Private Limited developed the product called as SET-Office. This product allows to create own set up where sponsor can manage clinical development program. SET-Office will be customised according to project/study requirement to achieve the project goal. SET-Office can provide people, processes and infrastructure across multiple therapeutic areas and function as an extension of your clinical research department. SET-Office will provides an option to establish clinical and medical affairs department for specific clinical trial project, which will be having complete control by sponsor. If you would like to understand more in detail about this product then please contact us on contact@abiogenesisclinpharm.com

Abiogenesis Clinpharm successfully completed one more biosimilar Phase III study.
Abiogenesis Clinpharm successfully completed the safety, efficacy , Immunogenicity and Pharmacokinetics evaluation of one of the biosimilar molecule in patients with Rheumatoid Arthritis. This biosimilar is a recombinant human monoclonal antibody binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Clinical trial was conducted in sites across India. As a specialized CRO in Biosimilar and Vaccine, this is one more addition of Biosimilar clinical trial experience in Abiogenesis Clinpharm.